Strategic Partnerships Target academia and biotech research labs that rely on NGS library preparation and indexing solutions, leveraging Swift’s established collaborations and historic acquisition by IDT to position Swift as a complementary vendor for library prep, targeted sequencing, and metagenomics workflows.

Product Expansion Pitch expansion opportunities around Swift Normalase Unique Dual Indexing Plates and 2S Turbo v2 library kits for metagenomics and whole-genome/exome projects, emphasizing higher multiplexing capacity and compatibility with leading Illumina platforms.

Market Growth Capitalize on Swift’s diversified industry reach (agrigenomics, pharmaceutical, oncology, academic research) to credential multi-industry use cases and cross-sell complementary sample prep tools to labs expanding sequencing workloads post-2021 partnerships.

Global Reach Highlight collaboration potential with SPT Labtech and international distribution partners to deliver streamlined sample prep solutions, offering bundled instrumentation and reagents to labs seeking end-to-end NGS workflows.

Financial Readiness Approach customers with growing sequencing budgets by framing Swift as an innovative, well-funded player with substantial funding and a $1M–$10M revenue range, suitable for mid-market lab adoption and scalable procurement through existing distributors.